Features of the course of COVID-19 in patients with comorbid pathology
https://doi.org/10.21518/2079-701X-2022-16-6-44-49
Abstract
Comorbidity is an important problem of modern medicine, the study of which is a priority for public health. According to the literature, the prevalence of comorbidity reaches a third of the population in some countries, while there is a tendency for an increase in the number of such patients in all age groups. In the context of the COVID-19 pandemic, the presence of comorbidity in patients is a significant risk factor affecting the course and prognosis of a new coronavirus infection; at the same time, it is comorbid patients who belong to the most vulnerable group. The review presents data indicating a significant impact of comorbid pathologies on an increase in the number of complications and mortality; the most common combinations of diseases in patients with a new coronavirus infection were analyzed. There is an increase in the prevalence of comorbidity in all age groups, which dictates the need to develop an integrated interdisciplinary approach for such patients. The vast majority of clinical guidelines for the treatment of comorbidities in COVID-19 are mainly focused on individual diseases, which limits the use of these algorithms in comorbid patients. Due to the high risk of contracting a viral infection, as well as the frequent development of complications and mortality in comorbid patients, preventive measures should be focused simultaneously on two tasks: measures aimed at preventing infection with COVID-19 and compensating for comorbid pathology. In the case of SARS-CoV-2 infection, careful monitoring of such patients, most often in a hospital setting, is necessary in order to prevent complications and adverse outcomes.
About the Authors
M. M. Sharipova
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Cand. Sci. (Med.), Аssistant of the Department of Nervous Diseases,
20, Bldg. 1, Delegatskaya St., Moscow, 127473
M. V. Ivkina
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Cand. Sci. (Med.), Senior Teacher of the Department of Normal Physiology and Medical Physics,
20, Bldg. 1, Delegatskaya St., Moscow, 127473
A. N. Arkhangelskaia
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Cand. Sci. (Med.), Аssociate Рrofessor of the UNESCO Department “Healthy Lifestyle – the Key to Successful Development”,
20, Bldg. 1, Delegatskaya St., Moscow, 127473
K. G. Gurevich
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Dr. Sci. (Med.), Рrofessor of the Russian Academy of Sciences, Head of the UNESCO Department “Healthy Lifestyle – the Key to Successful Development”,
20, Bldg. 1, Delegatskaya St., Moscow, 127473
I. V. Maev
Yevdokimov Moscow State University of Medicine and Dentistry
Russian Federation
Russian Federation
Dr. Sci. (Med.), Рrofessor, Academician of the Russian Academy of Sciences, Prorector for Academic Affairs, Head of the Department of Internal Diseases Propaedeutics and Gastroenterology,
20, Bldg. 1, Delegatskaya St., Moscow, 127473
References
1. Nagornykh A.M., Tyumentsev A.I., Tyumentseva M.A., Akimkin V.G. SARS, SARS again, and MERS. Review of animal models of human respiratory syndromes caused by coronavirus infections. Zhurnal Mikrobiologii, Epidemiologii i Immunobiologii. 2020;97(5):431–444. (In Russ.) https://doi.org/10.36233/0372-9311-2020-97-5-6.
2. Ejaz H., Alsrhani A., Zafar A., Javed H., Junaid K., Abdalla A.E. et al. COVID-19 and comorbidities: Deleterious impact on infected patients. J Infect Public Health. 2020;13(12):1833–1839. https://doi.org/10.1016/j.jiph.2020.07.014.
3. Ng W.H., Tipih T., Makoah N.A., Vermeulen J.G., Goedhals D., Sempa J.B. et al. Comorbidities in SARS-CoV-2 Patients: a Systematic Review and Meta-Analysis. mBio. 2021;12(1):e03647–20. https://doi.org/10.1128/mBio.03647-20.
4. Jeong I.K., Yoon K.H., Lee M.K. Diabetes and COVID-19: Global and regional perspectives. Diabetes Res Clin Pract. 2020;166:108303. https://doi.org/10.1016/j.diabres.2020.108303.
5. Renu K., Prasanna P.L., Valsala Gopalakrishnan A. Coronaviruses pathogenesis, comorbidities and multi-organ damage – A review. Life Sci. 2020;255:117839. https://doi.org/10.1016/j.lfs.2020.117839.
6. Mit’kovskaya N., Grigorenko E., Ruzanov D., Statkevich T. Coronavirus infection COVID-19 and comorbidity. Science and Innovations. 2020;(7): 50–60. (In Russ.) https://doi.org/10.29235/1818-9857-2020-7-50-60.
7. Kostinov M.P., Shmitko A.D., Polishchuk V.B., Khromova E.A. Modern representations of the new coronavirus and the disease caused by SARSCOV-2. Infectious Diseases: News, Opinions, Training. 2020;9(2):33–42. (In Russ.) https://doi.org/10.33029/2305-3496-2020-9-2-33-42.
8. Khan M.M.A., Khan M.N., Mustagir M.G., Rana J., Islam M.S., Kabir M.I. Effects of underlying morbidities on the occurrence of deaths in COVID-19 patients: A systematic review and meta-analysis. J Glob Health. 2020;10(2):020503. https://doi.org/10.7189/jogh.10.020503.
9. Grinevich V.B., Gubonina I.V., Doshchitsin V.L., Kotovskaya Yu.V., Kravchuk Yu.A., Ped V.I. et al. Management of patients with comorbidity during novel coronavirus (COVID-19) pandemic. National Consensus Statement 2020. Cardiovascular Therapy and Prevention (Russian Federation). 2020;19(4):2630. (In Russ.) https://doi.org/10.15829/1728-8800-2020-2630.
10. Barh D., Aljabali A.A., Tambuwala M.M., Tiwari S., Serrano-Aroca Á., Alzahrani K.J. et al. Predicting COVID-19-Comorbidity Pathway CrosstalkBased Targets and Drugs: Towards Personalized COVID-19 Management. Biomedicines. 2021;9(5):556. https://doi.org/10.3390/biomedicines9050556.
11. McQueenie R., Foster H.M.E., Jani B.D., Katikireddi S.V., Sattar N., Pell J.P. et al. Multimorbidity, polypharmacy, and COVID-19 infection within the UK Biobank cohort. PLoS ONE. 2020;15(8):e0238091. https://doi.org/10.1371/journal.pone.0238091.
12. Cheng S., Zhao Y., Wang F., Chen Y., Kaminga A.C., Xu H. Comorbidities’ potential impacts on severe and non-severe patients with COVID-19: A systematic review and meta-analysis. Medicine (Baltimore). 2021;100(12):e24971. https://doi.org/10.1097/MD.0000000000024971.
13. Molochkov A.V., Karateev D.E., Ogneva E.Yu., Zul’karnaev A.B., Luchikhina E.L., Makarova I.V., Semenov D.Yu. Comorbidities and predicting the outcome of COVID-19: the treatment results of 13,585 patients hospitalized in the Moscow Region. Almanac of Clinical Medicine. 2020;48:1–10. (In Russ.) https://doi.org/10.18786/2072-0505-2020-48-040.
14. Das S., Anu K.R., Birangal S.R., Nikam A.N., Pandey A., Mutalik S., Joseph A. Role of comorbidities like diabetes on severe acute respiratory syndrome coronavirus-2: A review. Life Sci. 2020;258:118202. https://doi.org/10.1016/j.lfs.2020.118202.
15. Shostak N.A., Pravdyuk N.G., Klimenko A.A., Kondrashov A.A., Timofeev V.T. Osteoarthritis and associated pathology-clinical and pathogenetic associations. RMJ. Medical Review. 2019;3(11(II)):44–47. (In Russ.) Available at: https://www.rmj.ru/articles/revmatologiya/Osteoartrit_i_associirovannaya_patologiya__kliniko-patogeneticheskie_vzaimosvyazi/.
16. Oganov R.G., Denisov I.N., Simanenkov V.I., Bakulin I.G., Bakulina N.V., Boldueva S.A. et al. Comorbidities in practice. Clinical guidelines. Cardiovascular Therapy and Prevention (Russian Federation). 2017;16(6):5–56. (In Russ.) https://doi.org/10.15829/1728-8800-2017-6-5-ее56.
17. Nguyen H., Manolova G., Daskalopoulou C., Vitoratou S., Prince M., Prina A.M. Prevalence of multimorbidity in community settings: A systematic review and meta-analysis of observational studies. J Comorb. 2019;9:2235042X19870934. https://doi.org/10.1177/2235042X19870934.
18. Pati S., Mahapatra P., Kanungo S., Uddin A., Sahoo K.C. Managing Multimorbidity (Multiple Chronic Diseases) Amid COVID-19 Pandemic: A Community Based Study From Odisha, India. Front Public Health. 2021;8:584408. https://doi.org/10.3389/fpubh.2020.584408.
19. Cuschieri S., Grech S. At-risk population for COVID-19: multimorbidity characteristics of a European small Island state. Public Health. 2021;192:33–36. https://doi.org/10.1016/j.puhe.2020.12.012.
20. Nunes B.P., Souza A.S.S., Nogueira J., Andrade F.B., Thume E., Teixeira D.S.D.C. et al. Multimorbidity and population at risk for severe COVID-19 in the Brazilian Longitudinal Study of Aging. Cad Saude Publica. 2020;36(12):e00129620. https://doi.org/10.1590/0102-311X00129620.
21. Naumova L.A., Osipova O.N. Comorbidity: mechanisms of pathogenesis, clinical significance. Modern Problems of Science and Education. 2016;(5). (In Russ.) Available at: https://s.science-education.ru/pdf/2016/5/25301.pdf.
22. Fortin M., Bravo G., Hudon C., Vanasse A., Lapointe L. Prevalence of multimorbidity among adults seen in family practice. Ann Fam Med. 2005;3(3):223–228. https://doi.org/10.1370/afm.272.
23. Polozova E.I., Seskina A.A., Puzanova E.V., Domina E.N., Ovsyannikova I.S., Surkova I.A. Comorbide conditions in patients with arterial hypertension. Modern Problems of Science and Education. 2019;(4). (In Russ.) Available at: https://s.science-education.ru/pdf/2019/4/28955.pdf.
24. Sun Y., Guan X., Jia L., Xing N., Cheng L., Liu B. et al. Independent and combined effects of hypertension and diabetes on clinical outcomes in patients with COVID-19: A retrospective cohort study of Huoshen Mountain Hospital and Guanggu Fangcang Shelter Hospital. J Clin Hypertens (Greenwich). 2021;23(2):218–231. https://doi.org/10.1111/jch.14146.
25. Chesnikova A.I., Safronenko V.A., Skarzhinskaya N.S., Safronenko A.V., Kolomatskaya O.E. Features of arterial hypertension in patients with comorbidity. Medical Herald of the South of Russia. 2017;(1):32–38. (In Russ.) https://doi.org/10.21886/2219-8075-2017-1-32-38.
26. Shishkova V.N., Kapustina L.A. Problems of a Comorbid Patient: How to Choose a Proper Statin. Effective Pharmacotherapy. 2017;17(1):14–23. (In Russ.) Available at: https://www.umedp.ru/articles/problemy_komorbidnogo_patsienta_kak_vybrat_pravilnyy_statin.html.
27. Ferrannini E., Cushman W.C. Diabetes and hypertension: the bad companions. Lancet. 2012;380(9841):601–610. https://doi.org/10.1016/S0140-6736(12)60987-8.
28. Chazova I.E., Blinova N.V., Nevzorova V.A., Zhernakova Yu.V., Savenkov M.P., Oshchepkova E.V. et al. Russian Medical Society for Arterial Hypertension Expert Consensus: Hypertension and COVID-19. Systemic Hypertension. 2020;17(3):35–41. (In Russ.) https://doi.org/10.26442/207508 2X.2020.3.200362.
29. Melikhova S.P., Shevtsova V.I., Zuykova A.A., Kotova Yu.A. Studying of comorbid pathology at the 2 types diabetes as the complication of the metabolic syndrome. Russian Archive of Internal Medicine. 2018;8(5): 366–371. (In Russ.) https://doi.org/10.20514/2226-6704-2018-0-5-366-371.
30. Salazar M.R. Is hypertension without any other comorbidities an independent predictor for COVID-19 severity and mortality? J Clin Hypertens (Greenwich). 2021;23(2):232–234. https://doi.org/10.1111/jch.14144.
31. Dedov I.I., Shestakova M.V., Melnichenko G.A., Mazurina N.V., Andreeva E.N., Bondarenko I.Z. et al. Interdisciplinary clinical practice guidelines “Management of obesity and its comorbidities”. Obesity and Metabolism. 2021;18(1):5–99. (In Russ.) https://doi.org/10.14341/omet12714.
32. Bajgain K.T., Badal S., Bajgain B.B., Santana M.J. Prevalence of comorbidities among individuals with COVID-19: A rapid review of current literature. Am J Infect Control. 2021;49(2):238–246. https://doi.org/10.1016/j.ajic.2020.06.213.
33. Mair F.S., Foster H.M., Nicholl B.I. Multimorbidity and the COVID-19 pandemic –An urgent call to action. J Comorb. 2020;10:2235042X20961676. https://doi.org/10.1177/2235042X20961676.
34. Nanda S., Toussaint L., Vincent A., Fischer K.M., Hurt R., Schroeder D.R. et al. A Midwest COVID-19 Cohort for the Evaluation of Multimorbidity and Adverse Outcomes from COVID-19. J Prim Care Community Health. 2021; 12:21501327211010991. https://doi.org/10.1177/21501327211010991.
35. Barron E., Bakhai C., Kar P., Weaver A., Bradley D., Ismail H. et al. Associations of type 1 and type 2 diabetes with COVID-19-related mortality in England: a whole population study. Lancet Diabetes Endocrinol. 2020;8(10):813–822. https://doi.org/10.1016/S2213-8587(20)30272-2.
36. Nandy K., Salunke A., Pathak S.K., Pandey A., Doctor C., Puj K. et al. Coronavirus disease (COVID-19): A systematic review and metaanalysis to evaluate the impact of various comorbidities on serious events. Diabetes Metab Syndr. 2020;14(5):1017–1025. https://doi.org/10.1016/j.dsx.2020.06.064.
37. Ecks S. Multimorbidity, Polyiatrogenesis, and COVID-19. Med Anthropol Q. 2020;34(4):488–503. https://doi.org/10.1111/maq.12626.
38. Edler C., Schroder A.S., Aepfelbacher M., Fitzek A., Heinemann A., Heinrich F. et al. Dying with SARS-CoV-2 infection-an autopsy study of the first consecutive 80 cases in Hamburg, Germany. Int J Legal Med. 2020;134(4):1275–1284. https://doi.org/10.1007/s00414-020-02317-w.
39. Barone M.T.U., Ngongo B., Harnik S.B., Oliveira L.X., Vegh D., de Luca P.V. et al. COVID-19 associated with diabetes and other noncommunicable diseases led to a global health crisis. Diabetes Res Clin Pract. 2021;171:108587. https://doi.org/10.1016/j.diabres.2020.108587.
40. Nanda S., Chacin Suarez A.S., Toussaint L., Vincent A., Fischer K.M., Hurt R. et al. Body Mass Index, Multi-Morbidity, and COVID-19 Risk Factors as Predictors of Severe COVID-19 Outcomes. J Prim Care Community Health. 2021;12:21501327211018559. https://doi.org/10.1177/21501327211018559.
41. Maddaloni E., D’Onofrio L., Alessandri F., Mignogna C., Leto G., Pascarella G. et al. Cardiometabolic multimorbidity is associated with a worse Covid-19 prognosis than individual cardiometabolic risk factors: a multicentre retrospective study (CoViDiab II). Cardiovasc Diabetol. 2020;19(1):164. https://doi.org/10.1186/s12933-020-01140-2.
42. Van Gerwen M., Alsen M., Little C., Barlow J., Genden E., Naymagon L., Tremblay D. Risk factors and outcomes of COVID-19 in New York City; a retrospective cohort study. J Med Virol. 2021;93(2):907–915. https://doi.org/10.1002/jmv.26337.
43. Guan W.J., Liang W.H., Zhao Y., Liang H.R., Chen Z.S., Li Y.M. et al. Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis. Eur Respir J. 2020;55(5):2000547. https://doi. org/10.1183/13993003.00547-2020.
44. Reilev M., Kristensen K.B., Pottegard A., Lund L.C., Hallas J., Ernst M.T. et al. Characteristics and predictors of hospitalization and death in the first 11 122 cases with a positive RT-PCR test for SARS-CoV-2 in Denmark: a nationwide cohort. Int J Epidemiol. 2020;49(5):1468–1481. https://doi.org/10.1093/ije/dyaa140.
45. Gromova O.A. Torshin I.Yu. The importance of zinc in maintaining the activity of antiviral innate immunity proteins: analysis of publications on COVID-19. Profilakticheskaya Meditsina. 2020;23(3):131–139. (In Russ.) https://doi.org/10.17116/profmed202023031131.
46. Sanchis-Gomar F., Lavie C.J., Mehra M.R., Henry B.M., Lippi G. Obesity and Outcomes in COVID-19: When an Epidemic and Pandemic Collide. Mayo Clin Proc. 2020;95(7):1445–1453. https://doi.org/10.1016/j.mayocp.2020.05.006.
47. Onder G., Rezza G., Brusaferro S. Case-fatality rate and characteristics of patients dying in relation to COVID-19 in Italy. J Am Med Assoc. 2020;323(18):1775–1776. https://doi.org/10.1001/jama.2020.4683.
48. Imam Z., Odish F., Gill I., O’Connor D., Armstrong J., Vanood A. et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020;288(4):469–476. https://doi.org/10.1111/joim.13119.
49. Muñoz P., Galar A., Catalán P., Valerio M., Aldamiz-Echevarría T., Cólliga C., Bouza E. The first 100 cases of COVID19 in a hospital in Madrid with a 2-month follow-up. Rev Esp Quimioter. 2020;33(5): 369–378. https://doi.org/10.37201/req/072.2020.
50. Fernández-Niño J.A., Guerra-Gómez J.A., Idrovo A.J. Multimorbidity patterns among COVID-19 deaths: proposal for the construction of etiological models. Rev Panam Salud Publica. 2020;44:e166. https://doi.org/10.26633/RPSP.2020.166.
51. Drapkina O.M., Samorodskaya I.V., Larina V.N. Challenges and perspectives of preventive medicine in primary care. Profilakticheskaya Meditsina. 2018;21(5):15–21. (In Russ.) https://doi.org/10.17116/profmed20182105115.
52. Marengoni A., Zucchelli A., Vetrano D.L., Armellini A., Botteri E., Nicosia F. et al. Beyond Chronological Age: Frailty and Multimorbidity Predict In-Hospital Mortality in Patients With Coronavirus Disease 2019. J Gerontol A Biol Sci Med Sci. 2021;76(3):e38–e45. https://doi.org/10.1093/gerona/glaa291.
Review
For citations:
Sharipova MM, Ivkina MV, Arkhangelskaia AN, Gurevich KG, Maev IV. Features of the course of COVID-19 in patients with comorbid pathology. Meditsinskiy sovet = Medical Council. 2022;(6):44-49. (In Russ.) https://doi.org/10.21518/2079-701X-2022-16-6-44-49
Views:
765
Email this article 